PRR32: A Drug Target / Disease Biomarker (G100130613)
PRR32: A Drug Target / Disease Biomarker
PRR32 is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell proliferation and has been implicated in a number of diseases, including cancer. As a drug target, PRR32 is a focus of ongoing research and development, with several companies currently working on developing drugs that target this protein.
PRR32 is a transcription factor that plays a role in the regulation of gene expression. It is composed of a N-terminal domain that contains a leucine-rich repeat, a core region that contains a zeta-helix, and a carboxylic acid tail. The N-terminal domain is responsible for the protein's ability to bind to DNA and the core region contains the protein's catalytic and regulatory activities.
PRR32 has been shown to be involved in a number of cellular processes, including cell growth, differentiation, and the regulation of the cell cycle. It has also been linked to a number of diseases, including cancer. For example, studies have shown that PRR32 is often overexpressed in cancer cells and that inhibiting its activity can lead to the growth arrest and differentiation of these cells.
As a drug target, PRR32 is a promising target for cancer treatment. Several companies have identified compounds that can inhibit PRR32's activity and are currently in the process of developing these compounds as potential drugs. These compounds have been shown to have a range of therapeutic effects, including the inhibition of cancer cell growth, the regression of cancer cells, and the improvement of immune responses.
In addition to its potential as a cancer drug, PRR32 is also being targeted for its role in the development of other diseases. For example, studies have shown that PRR32 is involved in the regulation of stem cell maintenance and that its activity can be inhibited to promote the differentiation of stem cells into functional tissues. This work has the potential to lead to the development of new treatments for a variety of diseases, including degenerative diseases and injuries.
Overall, PRR32 is a protein that is being targeted by several companies as a potential drug target for a range of diseases. Its unique structure and function make it an attractive target for research and development, and its potential as a cancer drug and therapeutic agent is driving ongoing research in this field. As the studies continue to emerge, it is likely that we will see the development of new treatments for a variety of diseases that are based on the regulation of PRR32.
Protein Name: Proline Rich 32
More Common Targets
PRRT3-AS1 | PRRX1 | PRSS35 | PRSS3P1 | PRSS46P | PRXL2C | PSMB7P1 | PSMB8-AS1 | PSMD10P1 | PSMD4P1 | PSMD6-AS2 | PSORS1C1 | PSORS1C2 | PSORS1C3 | PSTK | PTCHD1-AS | PTCHD3P2 | PTCRA | PTCSC3 | PTEN | PTENP1-AS | PTGES3L | PTGES3L-AARSD1 | PTGS2 | PTK2 | PTOV1 | PTOV1-AS1 | PTP4A1P2 | PTPRN2-AS1 | PTPRU | PUS7 | PWAR6 | PWWP2B | PXN-AS1 | QPCTL | QSOX2 | RAB11B-AS1 | RAB24 | RAB30-DT | RAB39A | RAB4B | RAB4B-EGLN2 | RAB6C-AS1 | RAD50 | RAD51-AS1 | RAD51L3-RFFL | RAET1E-AS1 | RAMP2-AS1 | RANBP3-DT | RANBP9 | RANP6 | RASA4 | RASA4B | RASA4DP | RASAL2-AS1 | RASGRP1 | RASSF6 | RASSF8-AS1 | RAX | RB1-DT | RBAK-RBAKDN | RBBP4P2 | RBBP4P6 | RBFOX1 | RBM11 | RBM12 | RBM14-RBM4 | RBM17P1 | RBM26-AS1 | RBM27 | RBM43P1 | RBM46 | RBM47 | RBM5 | RBM5-AS1 | RBM6 | RBM7 | RBMS3-AS3 | RBMX2P1 | RBPMS-AS1 | RC3H2 | RCAN1 | RCAN3AS | RCL1 | RELA | REM2 | RETREG1 | RETREG3 | REXO1L2P | RFESDP1 | RFFL | RHBDL3 | RHOF | RHOV | RILPL2 | RIMKLBP2 | RIN2 | RIPK4 | RIPPLY3 | RLIMP1